ArticleBreast cancer research : BCR2023

Targeting DCLK1 attenuates tumor stemness and evokes antitumor immunity in triple-negative breast cancer by inhibiting IL-6/STAT3 signaling.

Heshu Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.